PARP-targeted radiopharmaceuticals: advances in tumor PET imaging and targeted radiotherapy
10.3760/cma.j.cn321828-20250113-00011
- VernacularTitle:基于PARP的放射性药物在肿瘤PET显像与靶向放疗中的研究进展
- Author:
Hong XIANG
1
;
Yunhua WANG
1
Author Information
1. 中南大学湘雅二医院核医学科/PET影像中心，长沙 410011
- Publication Type:Journal Article
- Keywords:
Neoplasms;
Radiopharmaceuticals;
Poly (ADP-ribose) polymerase-1;
Positron-emission tomography;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2025;45(12):760-764
- CountryChina
- Language:Chinese
-
Abstract:
Poly (adenosine diphosphate-ribose) polymerase (PARP) is a series of enzymes with multiple functions widely present in the nuclei of eukaryotic cells, playing a crucial role in DNA damage repair, senility, chromatin remodeling, and transcriptional regulation. Notably, PARP-1 is overexpressed in tumor cells and serves as a pivotal factor in DNA damage repair. PARP inhibitors (PARPi) bind to the catalytic site of PARP-1, thereby inhibiting its activity and impeding DNA replication and repair in tumor cells, leading to therapeutic effects. However, the efficacy of PARPi is directly correlated with PARP expression levels in tumors. This review summarizes the current research and development status, existing challenges, and clinical application prospects of PET imaging agents and therapeutic radiopharmaceuticals targeting the PARP pathway.
